Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer
Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
It is a prospective multi-center trial, platinum-resistant ovarian cancer patients will be
randomized in two groups, one group will be treated with Apatinib plus Etoposide, the other
will be treated with Etoposide alone. It is aimed to see the efficacy and safety of Apatinib
plus Etoposide for the platinum-resistant ovarian cancer patients